Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Exactech Announces Successful First Revision Knee Replacement Surgery with Truliant® Instrumentation

Exactech Inc.
Posted on: 01 Nov 17

Exactech (Nasdaq: EXAC), a developer and producer of bone and joint restoration products and biologic solutions for extremities, knee and hip, is pleased to announce that the first revision knee surgery was performed using the company's award-winning Truliant® instrumentation. Orthopaedic surgeons will have a chance to experience the Truliant primary and revision systems through live mechanical demonstrations Nov. 2-5 at the American Association of Hip and Knee Surgeons (AAHKS) Annual Meeting, Booth #908 in Dallas, Texas.

The first surgery was performed by revision knee replacement specialist Ronald Hillock, MD, at the Nevada Orthopedic and Spine Center in Las Vegas. According to Dr. Hillock, “The case ran smoothly, and I was able to re-establish the patient’s joint line in just over an hour. Truliant is a well-thought-out, comprehensive system that allowed me to easily position the implant in the optimal position for the patient. The new offset couplers and metaphyseal cones allows for managing the complexities of implant fixation and bone loss.”

Developed through close collaboration with a team of design surgeons and Exactech engineers, Truliant supports both mechanical and computer-assisted surgical approaches and now addresses the continuum of total knee arthroplasty – from primary to revision.

“In designing Truliant, we were met with the paradox of trying to be simple and easy to understand, while still providing the surgeon and patient with all the options they need,” said Daniel C. Allison, MD, oncologic orthopaedic surgeon and Truliant design team member. “I think Exactech did a great job of bringing those things together and threading that needle, so that everything is intuitive without being overly complex. Combining that simplicity, while maintaining a wide variety of options was a hard challenge, but Exactech mastered it beautifully.”

The Truliant primary knee system made its clinical debut in May and has been used in more than 600 surgeries during the pilot launch. Both the primary and revision systems are expected to have full U.S. market availability in 2018. For more information, visit www.TruliantKnee.com.

About Exactech

Based in Gainesville, Fla., Exactech develops and markets orthopaedic implant devices, related surgical instruments and biologic materials and services to hospitals and physicians. The company manufactures many of its orthopaedic devices at its Gainesville facility. Exactech’s orthopaedic products are used in the restoration of bones and joints that have deteriorated as a result of injury or diseases such as arthritis. Exactech markets its products in the United States, in addition to more than 30 markets in Europe, Latin America, Asia and the Pacific. Additional information about Exactech can be found at http://www.exac.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20171101006434/en/

Business Wire
www.businesswire.com

Last updated on: 01/11/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.